RxDoctor Payments Data

Edward Braunstein, MD

Ophthalmology · New York, NYNPI 1003949322

Payments from drug & device makers

$3,427in general payments, 2019–2025

Across 163 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$736
  • Sun Pharmaceutical Industries Inc.$559
  • Mallinckrodt Hospital Products Inc.$463
  • Bausch & Lomb Americas Inc.$444
  • Oyster Point Pharma, Inc.$336
  • Johnson & Johnson Surgical Vision, Inc.$198
  • plus $691 from 10 others

What the payments were for

  • Food & beverage$3,427100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,427 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$72,362
Medicare patients
636
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast3,605$2,596,064
RestasisCyclosporine2,006$1,495,553
MieboPerfluorohexyloctane/Pf762$734,218
IyuzehLatanoprost/Pf962$408,654
VyzultaLatanoprostene Bunod884$290,121
TyrvayaVarenicline Tartrate372$227,082
CequaCyclosporine274$154,808
Cyclosporine333$93,363
CombiganBrimonidine Tartrate/Timolol323$75,703
LumiganBimatoprost220$58,525
MounjaroTirzepatide30$35,138
Latanoprost2,785$16,591
Bepotastine Besilate125$16,007
VevyeCyclosporine17$11,894
Brimonidine Tartrate433$10,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$444$3,620,4035,251 claims
AbbVieRestasis, Combigan, Lumigan$736$1,629,7812,549 claims
Thea Pharma Inc.Iyuzeh$105$408,654962 claims
Oyster Point Pharma, Inc.Tyrvaya$336$227,082372 claims
Sun Pharmaceutical Industries Inc.Cequa$559$154,808274 claims
Harrow Eye, LLCVevye$52$11,89417 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$19$10,47533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →